Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) has become the most important drug-resistant microbial pathogen in countries throughout the world. Morbidity and mortality due to MRSA infections continue to increase despite efforts to improve infection control measures and to develop new antibiotics. Therefore alternative antimicrobial strategies that do not give rise to development of resistance are urgently required. A group of therapeutic interventions has been developed in the field of photomedicine with the common theme that they rely on electromagnetic radiation with wavelengths between 200 and 1000 nm broadly called “light”. These techniques all use simple absorption of photons by specific chromophores to deliver the killing blow to microbial cells while leaving the surrounding host mammalian cells relatively unharmed. Photodynamic inactivation uses dyes called photosensitizers (PS) that bind specifically to MRSA cells and not host cells, and generate reactive oxygen species including singlet oxygen and singlet oxygen upon illumination. Sophisticated molecular strategies to target the PS to MRSA cells have been designed. Ultraviolet C radiation can damage microbial DNA without unduly harming host DNA. Blue light can excite endogenous porphyrins and flavins in MRSA cells that are not present in host cells. Near-infrared lasers can interfere with microbial membrane potentials without raising the temperature of the tissue. Taken together these innovative approaches towards harnessing the power of light suggest that the ongoing threat of MRSA may eventually be defeated.
Keywords: Photodynamic therapy, MRSA, PDI, blue light, UV light, photosensitizer, multi-drug efflux pump.
Current Pharmaceutical Design
Title:Harnessing the Power of Light to Treat Staphylococcal Infections Focusing on MRSA
Volume: 21 Issue: 16
Author(s): Tanupriya Agrawal, Pinar Avci, Gaurav K. Gupta, Ardeshir Rineh, Shanmugamurthy Lakshmanan, Vincent Batwala, George P Tegos and Michael R. Hamblin
Affiliation:
Keywords: Photodynamic therapy, MRSA, PDI, blue light, UV light, photosensitizer, multi-drug efflux pump.
Abstract: Methicillin-resistant Staphylococcus aureus (MRSA) has become the most important drug-resistant microbial pathogen in countries throughout the world. Morbidity and mortality due to MRSA infections continue to increase despite efforts to improve infection control measures and to develop new antibiotics. Therefore alternative antimicrobial strategies that do not give rise to development of resistance are urgently required. A group of therapeutic interventions has been developed in the field of photomedicine with the common theme that they rely on electromagnetic radiation with wavelengths between 200 and 1000 nm broadly called “light”. These techniques all use simple absorption of photons by specific chromophores to deliver the killing blow to microbial cells while leaving the surrounding host mammalian cells relatively unharmed. Photodynamic inactivation uses dyes called photosensitizers (PS) that bind specifically to MRSA cells and not host cells, and generate reactive oxygen species including singlet oxygen and singlet oxygen upon illumination. Sophisticated molecular strategies to target the PS to MRSA cells have been designed. Ultraviolet C radiation can damage microbial DNA without unduly harming host DNA. Blue light can excite endogenous porphyrins and flavins in MRSA cells that are not present in host cells. Near-infrared lasers can interfere with microbial membrane potentials without raising the temperature of the tissue. Taken together these innovative approaches towards harnessing the power of light suggest that the ongoing threat of MRSA may eventually be defeated.
Export Options
About this article
Cite this article as:
Agrawal Tanupriya, Avci Pinar, Gupta K. Gaurav, Rineh Ardeshir, Lakshmanan Shanmugamurthy, Batwala Vincent, Tegos P George and Hamblin R. Michael, Harnessing the Power of Light to Treat Staphylococcal Infections Focusing on MRSA, Current Pharmaceutical Design 2015; 21 (16) . https://dx.doi.org/10.2174/1381612821666150310102318
DOI https://dx.doi.org/10.2174/1381612821666150310102318 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Telomeres, Senescence and Longevity: The Role of Oxidative Stress and Antioxidants
Current Pharmacogenomics Effect of Dipeptidyl Peptidase-4 Inhibitors on Plasma Adiponectin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Current Medicinal Chemistry Artificial Intelligence, Big Data and Machine Learning Approaches in Precision Medicine & Drug Discovery
Current Drug Targets NF-κB Blockers Gifted by Mother Nature: Prospectives in Cancer Cell Chemosensitization
Current Pharmaceutical Design Docking Prediction for Luteolin Inhibiting TNF-α and NF-κB Pathway
Letters in Drug Design & Discovery Coronary Intravascular Ultrasound (IVUS): Contemporary Applications and Bases for the Future
Recent Patents on Medical Imaging Bacteriochlorophyll a and Its Derivatives: Chemistry and Perspectives for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry D3 Dopamine Receptor and Essential Hypertension
Current Hypertension Reviews Nitroso-Redox Balance and Modulation of Basal Myocardial Function: An Update from the Italian Society of Cardiovascular Research (SIRC)
Current Drug Targets DNA Repair Proteins as Molecular Therapeutics for Oxidative and Alkylating Lung Injury
Current Gene Therapy Nanotechnology approaches for pain therapy through transdermal drug delivery
Current Pharmaceutical Design Complications of Infective Endocarditis
Cardiovascular & Hematological Disorders-Drug Targets Hyperhomocysteinemia and Endothelial Dysfunction
Current Hypertension Reviews Pharmacological Strategies for Inhibition of Thrombin Activity
Current Pharmaceutical Design Chemical and Radiochemical Considerations in Radiolabeling with α-Emitting Radionuclides
Current Radiopharmaceuticals Phosphodiesterase Type 5 Inhibitors: Unmet Needs
Current Pharmaceutical Design Glaucoma Disease: A Survey
Current Medical Imaging Evaluation of Post-Surgical Cognitive Function and Protein Fingerprints in the Cerebro-Spinal Fluid Utilizing Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass-Spectrometry (SELDI-TOF MS) After Coronary Artery Bypass Grafting: Review of Proteomic Analytic Tools and Introducing a New Syndrome
Current Medicinal Chemistry Emerging Role of microRNA in Neuropathic Pain
Current Drug Metabolism Gene Delivery by Functional Inorganic Nanocarriers
Recent Patents on DNA & Gene Sequences